, Volume 22, Issue 11, pp 1344–1352 | Cite as

The Btk-dependent PIP5K1γ lipid kinase activation by Fas counteracts FasL-induced cell death

  • Aurélie Rossin
  • Nadia Lounnas
  • Jérôme Durivault
  • Giorgia Miloro
  • Laurent Gagnoux-Palacios
  • Anne-Odile HueberEmail author
Short Communication


The Fas/FasL system plays a critical role in death by apoptosis and immune escape of cancer cells. The Fas receptor being ubiquitously expressed in tissues, its apoptotic-inducing function, initiated upon FasL binding, is tightly regulated by several negative regulatory mechanisms to prevent inappropriate cell death. One of them, involving the non-receptor tyrosine kinase Btk, was reported mainly in B cells and only poorly described. We report here that Btk negatively regulates, through its tyrosine kinase activity, the FasL-mediated cell death in epithelial cell lines from colon cancer origin. More importantly, we show that Btk interacts not only with Fas but also with the phosphatidylinositol-4-phosphate 5-kinase, PIP5K1γ, which, upon stimulation by Fas ligand, is responsible of a rapid and transient synthesis of phosphatidylinositol-4,5-bisphosphate (PI(4,5)P2). This production requires both the presence and the tyrosine kinase activity of Btk, and participates in the negative regulation of FasL-mediated cell death since knocking down PIP5K1γ expression significantly strengthens the apoptotic signal upon FasL engagement. Altogether, our data demonstrate the cooperative role of Btk and PIP5K1γ in a FasL-induced PI(4,5)P2 production, both proteins participating to the threshold setting of FasL-induced apoptotic commitment in colorectal cell lines.


Fas Btk PIP5K1γ PI(4,5)P2 Cell death 



We are grateful to Bernard Payrastre for discussion and input at the initial phase of this work, to Marcel Deckert for providing us the mouse Btk expression vector and to Sébastien Huault for technical assistance. The authors acknowledge Agnès Loubat (Plateforme de Cytométrie Cyan, iBV, Université Côte d’Azur) for advises and assistance.


This work was supported by institutional funds from the Centre National de la Recherche Scientifique (CNRS), the Institut National de la Santé et de la Recherche Medicale (Inserm) and by grants from the Institut National du Cancer (INCa) (Grant No. 2009-197) and the Agence Nationale de la Recherche (ANR) (Grant No. ANR-10-BLAN-1226; LABEX SIGNALIFE program Grant No. ANR-11-LABX-0028-01).

Supplementary material

10495_2017_1415_MOESM1_ESM.tiff (1.2 mb)
Supplementary Figure 1—(a) Efficient Btk knock down was assessed by immunoblot in the indicated cell lines. (b) HCT15, HT29 and SW48 cells transfected with Btk si RNA were exposed to indicated doses of TRAIL crosslinked with M2 (1 ng/ml) and the percentage of cell death was determined by flow cytometry quantification of sub-G1 particles. (c) SW48, HT29 and HCT15 cells pre-treated for 2 hours with DMSO or Ibrutinib (1 and 3 µM) were incubated for 5 hours with indicated doses of FasL or TRAIL crosslinked with M2 (1 µg/ml). The percentage of cell death was assessed as in b. (TIFF 1192 KB)
10495_2017_1415_MOESM2_ESM.tiff (855 kb)
Supplementary Figure 2—(a) Efficient PIP5K1γ knock down was assessed by immunoblot in the indicated cell lines. (b) HCT15 and HT29 cells transfected with PIP5K1γ si RNA were exposed to indicated doses of TRAIL crosslinked with M2 (1 µg/ml) and the percentage of cell death was determined by flow cytometry quantification of sub-G1 particles. (TIFF 854 KB)


  1. 1.
    Kischkel FC, Hellbardt S, Behrmann I et al (1995) Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J 14:5579–5588PubMedPubMedCentralGoogle Scholar
  2. 2.
    Krammer PH (2000) CD95’s deadly mission in the immune system. Nature 407:789–795CrossRefPubMedGoogle Scholar
  3. 3.
    Ehrenschwender M, Wajant H (2009) The role of FasL and Fas in health and disease. Adv Exp Med Biol 647:64–93CrossRefPubMedGoogle Scholar
  4. 4.
    Peter ME, Budd RC, Desbarats J et al (2007) The CD95 receptor: apoptosis revisited. Cell 129:447–450CrossRefPubMedGoogle Scholar
  5. 5.
    Sato T, Irie S, Kitada S, Reed JC (1995) FAP-1: a protein tyrosine phosphatase that associates with Fas. Science 268:411–415CrossRefPubMedGoogle Scholar
  6. 6.
    Daigle I, Yousefi S, Colonna M, Green DR, Simon HU (2002) Death receptors bind SHP-1 and block cytokine-induced anti-apoptotic signaling in neutrophils. Nat Med 8:61–67CrossRefPubMedGoogle Scholar
  7. 7.
    Irmler M, Thome M, Hahne M et al (1997) Inhibition of death receptor signals by cellular FLIP. Nature 388:190–195CrossRefPubMedGoogle Scholar
  8. 8.
    Vassilev A, Ozer Z, Navara C, Mahajan S, Uckun FM (1999) Bruton’s tyrosine kinase as an inhibitor of the Fas/CD95 death-inducing signaling complex. J Biol Chem 274:1646–1656CrossRefPubMedGoogle Scholar
  9. 9.
    López-Herrera G, Vargas-Hernández A, González-Serrano ME et al (2014) Bruton’s tyrosine kinase–an integral protein of B cell development that also has an essential role in the innate immune system. J Leukoc Biol 95:243–250CrossRefPubMedGoogle Scholar
  10. 10.
    Mohamed AJ, Yu L, Bäckesjö CM et al (2009) Bruton’s tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain. Immunol Rev 228:58–73CrossRefPubMedGoogle Scholar
  11. 11.
    Saito K, Tolias KF, Saci A et al (2003) BTK regulates PtdIns-4,5-P2 synthesis: importance for calcium signaling and PI3K activity. Immunity 19:669–678CrossRefPubMedGoogle Scholar
  12. 12.
    Smith CI (2016) From identification of the BTK kinase to effective management of leukemia. Oncogene 36:2045CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Grassilli E, Pisano F, Cialdella A et al (2016) A novel oncogenic BTK isoform is overexpressed in colon cancers and required for RAS-mediated transformation. Oncogene 35:4368–4378CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Guo W, Liu R, Bhardwaj G et al (2014) Targeting Btk/Etk of prostate cancer cells by a novel dual inhibitor. Cell Death Dis 5:e1409CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Wang X, Wong J, Sevinsky CJ et al (2016) Bruton’s tyrosine kinase inhibitors prevent therapeutic escape in breast cancer cells. Mol Cancer Ther 15:2198–2208CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Middendorp S, Dingjan GM, Maas A, Dahlenborg K, Hendriks RW (2003) Function of Bruton’s tyrosine kinase during B cell development is partially independent of its catalytic activity. J Immunol 171:5988–5996CrossRefPubMedGoogle Scholar
  17. 17.
    Tumang JR, Negm RS, Solt LA et al (2002) BCR engagement induces Fas resistance in primary B cells in the absence of functional Bruton’s tyrosine kinase. J Immunol 168:2712–2719CrossRefPubMedGoogle Scholar
  18. 18.
    Khare A, Viswanathan B, Gund R et al (2011) Role of Bruton’s tyrosine kinase in macrophage apoptosis. Apoptosis 16:334–346CrossRefPubMedGoogle Scholar
  19. 19.
    Schmidt U, van den Akker E, Parren-van Amelsvoort M et al (2004) Btk is required for an efficient response to erythropoietin and for SCF-controlled protection against TRAIL in erythroid progenitors. J Exp Med 199:785–795CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    McNamee HP, Ingber DE, Schwartz MA (1993) Adhesion to fibronectin stimulates inositol lipid synthesis and enhances PDGF-induced inositol lipid breakdown. J Cell Biol 121:673–678CrossRefPubMedGoogle Scholar
  21. 21.
    Honda A, Nogami M, Yokozeki T et al (1999) Phosphatidylinositol 4-phosphate 5-kinase alpha is a downstream effector of the small G protein ARF6 in membrane ruffle formation. Cell 99:521–532CrossRefPubMedGoogle Scholar
  22. 22.
    Di Paolo G, De Camilli P (2006) Phosphoinositides in cell regulation and membrane dynamics. Nature 443:651–657CrossRefPubMedGoogle Scholar
  23. 23.
    Lee KH, Feig C, Tchikov V et al (2006) The role of receptor internalization in CD95 signaling. EMBO J 25:1009–1023CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Chakrabandhu K, Hueber AO (2016) Fas versatile signaling and beyond: pivotal role of tyrosine phosphorylation in context-dependent signaling and diseases. Front Immunol 7:429CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Kwiatkowska K (2010) One lipid, multiple functions: how various pools of PI(4,5)P(2) are created in the plasma membrane. Cell Mol Life Sci 67:3927–3946CrossRefPubMedGoogle Scholar
  26. 26.
    Chakrabandhu K, Hérincs Z, Huault S et al (2007) Palmitoylation is required for efficient Fas cell death signaling. EMBO J 26:209–220CrossRefPubMedGoogle Scholar
  27. 27.
    Fais S, De Milito A, Lozupone F (2005) The role of FAS to ezrin association in FAS-mediated apoptosis. Apoptosis 10:941–947CrossRefPubMedGoogle Scholar
  28. 28.
    Iessi E, Zischler L, Etringer A et al (2015) Death receptor-induced apoptosis signalling regulation by ezrin is cell type dependent and occurs in a disc-independent manner in colon cancer cells. PLoS ONE 10:e0126526CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Zhu L, Derijard B, Chakrabandhu K, Wang BS, Chen HZ, Hueber AO (2014) Synergism of PI3K/Akt inhibition and Fas activation on colon cancer cell death. Cancer Lett 354:355–364CrossRefPubMedGoogle Scholar
  30. 30.
    Gao L, Gülcüler GS, Golbach L, Block H, Zarbock A, Martin-Villalba A (2016) Endothelial cell-derived CD95 ligand serves as a chemokine in induction of neutrophil slow rolling and adhesion. Elife 5:e18542PubMedPubMedCentralGoogle Scholar

Copyright information

© European Union 2017

Authors and Affiliations

  1. 1.Université Côte d’Azur, Institut de Biologie Valrose, CNRS UMR 7277, Inserm UMR 1091, Parc Valrose, Bâtiment des Sciences NaturellesNice Cedex2France

Personalised recommendations